학술논문
In CKD, once-daily empagliflozin reduced progression of kidney disease or CV death at 2 y.
Document Type
Article
Author
Source
Subject
*KIDNEY diseases
*EMPAGLIFLOZIN
*DISEASE progression
*CHRONIC kidney failure
*CHRONICALLY ill
*
*
*
*
Language
ISSN
0003-4819
Abstract
Source Citation: EMPA-KIDNEY Collaborative Group; Herrington WG, Staplin N, Wanner C, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388:117-27. 36331190 Clinical Impact Ratings: GIM/FP/GP: Cardiology: Nephrology: [ABSTRACT FROM AUTHOR]